Drug Search Results

BI-771716

Alternative Names: BI-771716, BI 771716, BI771716
Latest Update: 2025-02-25
Latest Update Note: News Article

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BI-771716

Countries in Clinic: Puerto Rico, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Geographic Atrophy|Macular Degeneration

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
VERDANT	P2	Recruiting	Geographic Atrophy\|Macular Degeneration	2026-12-16
Open Label, Non-randomized	P1	Completed	Macular Degeneration\|Geographic Atrophy	2024-05-24

Recent News Events

Date	Type	Title
02/25/2025	News Article	CDR-Life Announces Fifth Milestone Achievement with Boehringer Ingelheim in Geographic Atrophy
09/05/2024	News Article	Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
04/30/2024	News Article	CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial
12/06/2023	News Article	CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions